CordenPharma has committed to spend ~€900 million (~$ 981 million) over the next 3 years to grow its Peptide technology platform. These plans include two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions designed and built according to the pharmaceutical industry’s most stringent quality and technical standards for short and long peptide manufacturing, including Biologics License Applications (BLA) requireme...